The global clinical microbiology market is expected to reach USD 4.95 billion by 2023 from USD 3.63 billion in 2018 growing at a CAGR of 6.4% during forecast period. The technological advancements in the disease diagnostics, rising incidence of infectious diseases and growing outbreak of epidemics, and increased funding and public-private investments in the field of disease diagnosis are the key factors driving the growth of the clinical microbiology market during the forecast period.
Strategic analysis of the market developments between 2014 and 2018 revealed that growth strategies such as product launches and enhancements; acquisitions; agreements, partnerships, collaboration; and expansions were adopted by the market players to strengthen their product portfolios and maintain a competitive position in the clinical microbiology market. Among these business strategies, product launches & enhancements and partnerships & collaborations were the two most widely adopted growth strategies.
bioMérieux S.A. (France) held the leading position in the global clinical microbiology market in 2017. The company has a robust product portfolio and a strong geographical presence in more than 150 countries across the world. To maintain its leadership position in the market, the company has been focusing on R&D activities and product launches. In 2017, the company invested ~13% of its revenue in R&D activities, with the aim to improve product quality, accuracy, and reduce the overall throughput time required for a test. The company launched several products in the clinical testing space in the past four years, such as VITEK MS, FilmArray 2.0, VIDAS C. difficile GDH assay kit, GENE-UP diagnostic solution, ChromID Salmonella ELITE, and FilmArray Ebola test, among others.
Danaher Corporation (US) held the second position in the global clinical microbiology market in 2017. The company operates in the clinical microbiology testing market through its wholly owned subsidiaries— Beckman Coulter and Cepheid. Danaher is focusing on strengthening its position in the global clinical microbiology market mainly by adopting strategies such as acquisitions and new product launches. The acquisition of Beckman Coulter Inc. (a major player in the US life sciences and diagnostics market) in June 2011 helped the company strengthen its product portfolio and increase its share in the clinical microbiology testing market. The acquisition of Cepheid in November 2016 further helped to enhance the company’s position, expand its molecular diagnostic products portfolio, and increase its market share in the clinical microbiology testing market. The company also acquired Siemens Healthcare’s clinical microbiology business (July 2014) and Xitogen Technologies Inc. (April 2014) to strengthen its product offerings and geographic presence. The company launched several innovative products, such as DxM 6100 Autoplak Advanced System, Xpert Xpress Flu Test Kit, DxONE Clinical Information Management Tools, VERIS Human CMV Assay, and UniCel DxH Connected Workcell Solution, among others. These products have helped the company remain competitive in the microbiology testing market.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=219135367